Details of Disease

General Information of Disease (ID: DISJ6YIF)

Disease Name T-cell leukaemia
Synonyms T cell leukaemia (disease); T cell leukemia (disease); leukaemia (disease) of T cell; leukemia (disease) of T cell
Disease Class 2A90: Mature T-cell lymphoma
Definition A malignant disease of the T-lymphocytes in the bone marrow, thymus, and/or blood.
Disease Hierarchy
DISNAKFL: Leukemia
DIS65TYQ: Lymphoid leukemia
DIS17G9I: Leukocyte disorder
DISJ6YIF: T-cell leukaemia
ICD Code
ICD-11
ICD-11: 2A90
ICD-10
ICD-10: C86
Disease Identifiers
MONDO ID
MONDO_0005525
MESH ID
D015458
UMLS CUI
C0023492
MedGen ID
6064

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Mogamulizumab DMISH0Z Approved Monoclonal antibody [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Adcetris DMEDF2B Phase 3 NA [2]
Tamibarotene DM3G74J Phase 3 Small molecular drug [3]
BNZ-1 DM8JQZC Phase 2 Peptide [1]
DS-3201b DMI69E5 Phase 2 Small molecular drug [4]
CD4CAR DM09SW6 Phase 1 CAR T Cell Therapy [5]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
COR-D DMLXMCB Preclinical Small molecular drug [6]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 6 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
2-aminophenoxazine-3-one DMBVGAO Investigative Small molecular drug [7]
EAPB0203 DMB7685 Investigative Small molecular drug [8]
Hippuristanol DM0PV2Y Investigative Small molecular drug [9]
NK314 DMY729C Investigative Small molecular drug [10]
NSC 19630 DMLT8G9 Investigative Small molecular drug [11]
Torin2 DMC6U93 Investigative Small molecular drug [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 49 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CCR9 TTIPS8B Limited Biomarker [13]
DLL1 TT9CFQD Limited Genetic Variation [14]
F9 TTFEZ5Q Limited Biomarker [15]
IL2RB TT9721Y Limited Altered Expression [13]
ITGAL TT48WR6 Limited Altered Expression [16]
LMO2 TTFX379 Limited Biomarker [17]
LYN TT1RWNJ Limited Altered Expression [18]
MYB TT8V13P Limited Genetic Variation [19]
PSMB6 TT8EPLT Limited Genetic Variation [14]
PTPN2 TTY8PUS Limited Biomarker [20]
SERPINH1 TTPSWQG Limited Biomarker [21]
TCF3 TTULOD8 Limited Biomarker [22]
TRBC1 TT1DHW2 Limited Biomarker [23]
TXN TTZJ5U9 moderate Biomarker [24]
CD209 TTBXIM9 Strong Biomarker [25]
CD52 TTQT5S9 Strong Altered Expression [26]
CDC20 TTBKFDV Strong Altered Expression [27]
EGLN2 TTMHFRY Strong Biomarker [28]
FCGRT TTKLPHO Strong Biomarker [29]
FOXP3 TT1X3QF Strong Altered Expression [30]
FUT4 TTNV1KZ Strong Biomarker [31]
HCAR3 TT8WFXV Strong Biomarker [32]
IKZF2 TTKT5NV Strong Genetic Variation [33]
IL15RA TTGN89I Strong Altered Expression [34]
ITGB7 TTLT9XQ Strong Altered Expression [35]
ITK TT3C80U Strong Biomarker [36]
LAIR1 TTSI7A8 Strong Genetic Variation [37]
LCK TT860QF Strong Genetic Variation [38]
LRP1 TTF2V7I Strong Biomarker [39]
MTAP TTDBX7N Strong Biomarker [40]
NOTCH1 TTB1STW Strong Biomarker [41]
PIM3 TTCGOIN Strong Biomarker [42]
PMS1 TTX1ISF Strong Altered Expression [43]
RPSA TTLUW5B Strong Biomarker [39]
SATB1 TTLFRIC Strong Altered Expression [44]
SELL TT2IYXF Strong Biomarker [45]
STAT3 TTHJT3X Strong Biomarker [46]
TCL1A TTUKRDV Strong Biomarker [47]
TDP1 TT64IHJ Strong Biomarker [48]
TERF2 TT5XSLT Strong Biomarker [49]
THBS1 TTKI0H1 Strong Biomarker [50]
TNFRSF4 TTL31H0 Strong Altered Expression [51]
TRB TT84HCW Strong Genetic Variation [52]
USP44 TTJLTNM Strong Altered Expression [53]
WNK1 TTJ9UMX Strong Altered Expression [30]
CCR4 TT7HQD0 Definitive Altered Expression [54]
CD38 TTPURFN Definitive Genetic Variation [55]
CNTN2 TT2Z1WB Definitive Biomarker [42]
DEPTOR TTLYP6D Definitive Biomarker [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 49 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC44A1 DT3I2SU Strong Biomarker [57]
------------------------------------------------------------------------------------
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
SCLY DEH4TD6 Limited Biomarker [58]
------------------------------------------------------------------------------------
This Disease Is Related to 110 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BCL11B OT8KKCVJ Limited Genetic Variation [33]
CDKN2D OT2TTZPZ Limited Biomarker [15]
CEBPE OTKZA25M Limited Genetic Variation [59]
CUX1 OTU1LCNJ Limited Biomarker [60]
CYLD OT37FKH0 Limited Altered Expression [61]
GLIS2 OTOUUV1X Limited Biomarker [62]
IL2RG OTRZ3OMY Limited Genetic Variation [63]
LMO1 OTB59SKB Limited Biomarker [64]
LYL1 OTCNOV1M Limited Altered Expression [65]
MRPL28 OT4LUTZU Limited Genetic Variation [66]
MTCP1 OT4O23TK Limited Genetic Variation [67]
MYADM OTZTZI7P Limited Altered Expression [68]
NXT1 OT0VO6AY Limited Genetic Variation [66]
PLEK OTB73XXA Limited Biomarker [69]
SH2D1A OTLU49I5 Limited Biomarker [70]
CADM1 OTRWG9QS Disputed Altered Expression [30]
PTHLH OTI1JF13 Disputed Biomarker [71]
BCR OTCN76C1 moderate Genetic Variation [72]
TAL1 OTX4K6QZ moderate Altered Expression [73]
ADAM11 OTPTVW5W Strong Biomarker [74]
ADAM21 OTGBAVYU Strong Biomarker [75]
AMFR OTQRX7LC Strong Biomarker [76]
ASCC2 OT3B204T Strong Biomarker [77]
ATL2 OT93AUOO Strong Biomarker [57]
ATL3 OTQVFKMV Strong Biomarker [78]
AUTS2 OTAEXHSC Strong Biomarker [79]
CADM4 OT0TFMFE Strong Biomarker [80]
CCL1 OT23NON8 Strong Biomarker [81]
CCL28 OTY6XNQ7 Strong Biomarker [82]
CD151 OTF3UZS7 Strong Altered Expression [83]
CD3D OTRBLP0R Strong Altered Expression [84]
CHP1 OTHTXN1A Strong Biomarker [85]
CILK1 OTWOYEYP Strong Biomarker [86]
CMC4 OTT2YVJ7 Strong Altered Expression [87]
CNKSR3 OTXP4QH8 Strong Altered Expression [88]
DNTT OTFSEF12 Strong Altered Expression [89]
E2F4 OTB3JFH4 Strong Genetic Variation [90]
EIF4G1 OT2CF1E6 Strong Biomarker [91]
ELF2 OTEI347F Strong Biomarker [92]
FBXO7 OTGTN8TJ Strong Biomarker [93]
FOXE3 OTAUDKC1 Strong Biomarker [94]
FOXN1 OTE80D6I Strong Biomarker [95]
GIN1 OT6L79OO Strong Biomarker [96]
GORASP1 OTQS91S7 Strong Altered Expression [30]
GZMM OTEC5CWT Strong Biomarker [26]
HCLS1 OTX7WGYN Strong Biomarker [60]
HERPUD1 OT9EROL6 Strong Genetic Variation [97]
HIPK3 OT4WYQM2 Strong Biomarker [98]
HPR OTXSC9UB Strong Biomarker [99]
IFT172 OT12DW08 Strong Biomarker [100]
IRF4 OT1DHQ1P Strong Biomarker [101]
JARID2 OT14UM8H Strong Biomarker [102]
LBR OT1HG3HG Strong Biomarker [103]
LBX1 OTQJHICM Strong Genetic Variation [104]
LDB1 OT20EAPR Strong Biomarker [17]
LRSAM1 OTOKWR6C Strong Genetic Variation [105]
MAGI1 OTMV4ASV Strong Altered Expression [88]
MEF2C OTZGF1Y5 Strong Biomarker [106]
MPP1 OTA2ENZQ Strong Altered Expression [60]
MSH3 OTD3YPVL Strong Biomarker [43]
MVP OTJGHJRB Strong Altered Expression [39]
NCKIPSD OT24UORN Strong Biomarker [107]
NFE2L1 OT1QHOS2 Strong Altered Expression [48]
NOX5 OTHTH59G Strong Biomarker [108]
NRF1 OTOXWNV8 Strong Altered Expression [48]
NRK OTGR01FF Strong Altered Expression [109]
NRSN1 OT1KKXC8 Strong Biomarker [85]
OAS3 OT6E5FYS Strong Biomarker [77]
PIAS3 OT3TWH9R Strong Biomarker [110]
POLD4 OTG578YH Strong Biomarker [107]
POLE4 OTCMWUT6 Strong Biomarker [107]
POLG2 OTDBMZJB Strong Altered Expression [60]
POT1 OTNBXJCQ Strong Altered Expression [111]
PSMD12 OTWICA51 Strong Altered Expression [60]
PTCH2 OTOQ0K9V Strong Biomarker [93]
PTCRA OTQTO5QZ Strong Altered Expression [112]
PTPRA OTZA82J1 Strong Biomarker [39]
RAG2 OTG9UYTW Strong Biomarker [113]
RANBP3 OTI8ESC3 Strong Biomarker [114]
RASGRP1 OTX9WN2E Strong Altered Expression [115]
RASGRP4 OT15PWN4 Strong Biomarker [116]
RGS1 OTGXJYMG Strong Biomarker [117]
RPL10 OTBHOZGC Strong Genetic Variation [118]
SACM1L OT6ORKTD Strong Biomarker [119]
SART3 OTC1AM7S Strong Biomarker [77]
SHB OTF2HSC0 Strong Biomarker [120]
SIGLEC7 OTNDLURR Strong Biomarker [60]
SOAT1 OTB4Y5RJ Strong Biomarker [121]
SPOCK3 OTYSOOO7 Strong Altered Expression [122]
SPTAN1 OT6VY3A3 Strong Biomarker [123]
SYT1 OTVTPOI6 Strong Altered Expression [30]
TAF8 OTWWGCHV Strong Altered Expression [124]
TALDO1 OTDKV2S2 Strong Genetic Variation [105]
TARS1 OT0PWST5 Strong Biomarker [125]
TBPL1 OT4I143E Strong Biomarker [49]
TBPL2 OTDEC1KO Strong Altered Expression [126]
TCL1B OT4CSO39 Strong Biomarker [47]
TCTA OT0AH12O Strong Genetic Variation [127]
TINF2 OT861N2N Strong Altered Expression [111]
TLX2 OTPFAUM8 Strong Biomarker [104]
TLX3 OTBUHHK3 Strong Posttranslational Modification [94]
TMED2 OTBLO7RW Strong Biomarker [85]
TMED9 OTYGAQS0 Strong Biomarker [128]
TPPP OTCFMSUF Strong Biomarker [128]
CBFA2T2 OTNOIB23 Definitive Biomarker [129]
ERVW-1 OTWV8DXJ Definitive Biomarker [130]
ETV6 OTCZMG61 Definitive Genetic Variation [131]
HBZ OTMHGFSS Definitive Altered Expression [132]
NOMO1 OTIALEI1 Definitive Biomarker [129]
TMEM132D OTV6I4Z0 Definitive Altered Expression [133]
------------------------------------------------------------------------------------
⏷ Show the Full List of 110 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04797780) SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04102150) Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT03829540) CD4CAR for CD4+ Leukemia and Lymphoma. U.S. National Institutes of Health.
6 ClinicalTrials.gov (NCT04022863) Ovarium Cancer Detection by TEP's and ctDNA. U.S. National Institutes of Health.
7 Anticancer effects of phenoxazine derivatives revealed by inhibition of cell growth and viability, disregulation of cell cycle, and apoptosis induction in HTLV-1-positive leukemia cells. J Pharmacol Sci. 2009 May;110(1):87-97.
8 EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7.
9 Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A. Translation (Austin). 2016 Jan 4;4(1):e1137381.
10 NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase. Blood. 2011 Mar 31;117(13):3575-84.
11 WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol. 2016 Nov 9;9(1):121.
12 Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102.
13 The mechanism of chemokine receptor 9 internalization triggered by interleukin 2 and interleukin 4.Cell Mol Immunol. 2009 Jun;6(3):181-9. doi: 10.1038/cmi.2009.25.
14 Human T cell leukemias with continuous V(D)J recombinase activity for TCR-delta gene deletion.J Immunol. 1997 Nov 1;159(9):4341-9.
15 Frequent lack of antibodies against human T-cell leukemia virus type I gag proteins p24 or p19 in sera of patients with adult T-cell leukemia.J Cancer Res Clin Oncol. 1989;115(3):279-84. doi: 10.1007/BF00391703.
16 Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells.Blood. 1998 May 15;91(10):3909-19.
17 LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.Mol Cell Biol. 2015 Nov 23;36(3):488-506. doi: 10.1128/MCB.00901-15. Print 2016 Feb 1.
18 Phenotypic changes induced by interleukin-2 (IL-2) and IL-3 in an immature T-lymphocytic leukemia are associated with regulated expression of IL-2 receptor beta chain and of protein tyrosine kinases LCK and LYN.Blood. 1992 Aug 15;80(4):1017-25.
19 New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.Cell Cycle. 2010 Aug 1;9(15):2986-95. doi: 10.4161/cc.9.15.12515. Epub 2010 Aug 28.
20 Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.
21 Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.Cancer Res. 1993 Dec 15;53(24):6067-73.
22 A Signature of Genomic Instability Resulting from Deficient Replication Licensing.PLoS Genet. 2017 Jan 3;13(1):e1006547. doi: 10.1371/journal.pgen.1006547. eCollection 2017 Jan.
23 Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome.AIDS. 2019 Jul 15;33(9):1421-1429. doi: 10.1097/QAD.0000000000002187.
24 The thioredoxin-1 system is essential for fueling DNA synthesis during T-cell metabolic reprogramming and proliferation.Nat Commun. 2018 May 10;9(1):1851. doi: 10.1038/s41467-018-04274-w.
25 DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.J Virol. 2006 May;80(10):4771-80. doi: 10.1128/JVI.80.10.4771-4780.2006.
26 Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.Blood. 2013 Mar 14;121(11):2029-37. doi: 10.1182/blood-2012-05-427773. Epub 2013 Jan 15.
27 HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule.Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):63-8. doi: 10.1073/pnas.0406424101. Epub 2004 Dec 27.
28 Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.J Cell Sci. 2011 Jul 1;124(Pt 13):2208-19. doi: 10.1242/jcs.080523.
29 Cytogenetic implication in adult T-cell leukemia. A hypothesis of leukemogenesis.Cancer Genet Cytogenet. 1991 Jan;51(1):131-6. doi: 10.1016/0165-4608(91)90019-q.
30 Detection of human T lymphotropic virus type-I bZIP factor and tax in the salivary glands of Sjgren's syndrome patients.Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):51-60. Epub 2018 Mar 20.
31 Transcriptional regulation of expression of carbohydrate ligands for cell adhesion molecules in the selectin family.Adv Exp Med Biol. 2001;491:267-78. doi: 10.1007/978-1-4615-1267-7_18.
32 Molecular cloning and sequence analysis of cDNA and genomic DNA for the human cone transducin alpha subunit.FEBS Lett. 1991 Oct 21;291(2):245-8. doi: 10.1016/0014-5793(91)81294-i.
33 HELIOS-BCL11B fusion gene involvement in a t(2;14)(q34;q32) in an adult T-cell leukemia patient.Cancer Genet. 2012 Jul-Aug;205(7-8):356-64. doi: 10.1016/j.cancergen.2012.04.006.
34 Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R.Blood. 2011 Apr 14;117(15):4032-40. doi: 10.1182/blood-2010-09-307504. Epub 2011 Feb 8.
35 Identification of an adhesion molecule expressed on adult T cell leukemia cells derived from a patient with gastrointestinal involvement: implication for a possible role of integrin beta 7 in leukemic cell infiltration into intestinal mucosa.J Clin Immunol. 1999 May;19(3):186-93. doi: 10.1023/a:1020507828066.
36 Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).Eur J Med Chem. 2019 Jul 1;173:167-183. doi: 10.1016/j.ejmech.2019.03.055. Epub 2019 Mar 26.
37 Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.Leuk Res. 2005 Mar;29(3):253-62. doi: 10.1016/j.leukres.2004.07.012.
38 Targeting mature T cell leukemia: new understanding of molecular pathways.Am J Pharmacogenomics. 2003;3(1):31-6. doi: 10.2165/00129785-200303010-00005.
39 Human T-cell lymphotropic virus type I Tax activates lung resistance-related protein expression in leukemic clones established from an adult T-cell leukemia patient.Exp Hematol. 2002 Apr;30(4):340-5. doi: 10.1016/s0301-472x(02)00775-0.
40 Lack of expression of MTAP in uncommon T-cell lymphomas.Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):306-9. doi: 10.1016/j.clml.2012.07.001.
41 USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.
42 Expression and significance of Pim-3 kinase in adult T-cell leukemia.Eur J Haematol. 2017 Dec;99(6):495-504. doi: 10.1111/ejh.12940. Epub 2017 Sep 11.
43 Reduced expression of human mismatch repair genes in adult T-cell leukemia.Am J Hematol. 2005 Feb;78(2):100-7. doi: 10.1002/ajh.20259.
44 Decreased SATB1 expression promotes AML cell proliferation through NF-B activation.Cancer Cell Int. 2019 May 17;19:134. doi: 10.1186/s12935-019-0850-x. eCollection 2019.
45 Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.Blood. 2001 May 15;97(10):3177-83. doi: 10.1182/blood.v97.10.3177.
46 Direct Targeting Options for STAT3 and STAT5 in Cancer.Cancers (Basel). 2019 Dec 3;11(12):1930. doi: 10.3390/cancers11121930.
47 T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways.Front Oncol. 2018 Aug 13;8:317. doi: 10.3389/fonc.2018.00317. eCollection 2018.
48 HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia.Sci Rep. 2017 Oct 9;7(1):12849. doi: 10.1038/s41598-017-12924-0.
49 Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.Cancer Biol Ther. 2007 Aug;6(8):1186-92. doi: 10.4161/cbt.6.8.4381. Epub 2007 May 4.
50 Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis.An Bras Dermatol. 2017 Jul-Aug;92(4):573-574. doi: 10.1590/abd1806-4841.20176684.
51 Association of high levels of plasma OX40 with acute adult T-cell leukemia.Int J Hematol. 2019 Mar;109(3):319-327. doi: 10.1007/s12185-018-02580-z. Epub 2019 Jan 16.
52 The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children.Blood. 2007 Aug 15;110(4):1251-61. doi: 10.1182/blood-2006-12-064683. Epub 2007 Apr 23.
53 Overexpression of ubiquitin specific protease 44 (USP44) induces chromosomal instability and is frequently observed in human T-cell leukemia.PLoS One. 2011;6(8):e23389. doi: 10.1371/journal.pone.0023389. Epub 2011 Aug 11.
54 Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia.Oncoimmunology. 2017 Dec 11;7(3):e1405204. doi: 10.1080/2162402X.2017.1405204. eCollection 2018.
55 G-quadruplex structures formed at the HOX11 breakpoint region contribute to its fragility during t(10;14) translocation in T-cell leukemia.Mol Cell Biol. 2013 Nov;33(21):4266-81. doi: 10.1128/MCB.00540-13. Epub 2013 Sep 3.
56 DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia.Oncogene. 2017 Feb 23;36(8):1038-1047. doi: 10.1038/onc.2016.275. Epub 2016 Sep 5.
57 Human leukocyte antigen-class II-negative long-term cultured human T-cell leukemia virus type-I-infected T-cell lines with progressed cytological properties significantly induce superantigen-dependent normal T-cell proliferation.Pathol Int. 2005 May;55(5):264-72. doi: 10.1111/j.1440-1827.2005.01823.x.
58 Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice.Leukemia. 2001 Jan;15(1):141-7. doi: 10.1038/sj.leu.2401997.
59 Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.Cancer Genet Cytogenet. 2008 Dec;187(2):125-9. doi: 10.1016/j.cancergencyto.2008.08.008.
60 Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.Blood. 2002 Aug 15;100(4):1399-403. doi: 10.1182/blood-2002-01-0300.
61 Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia.Cell Cycle. 2011 Apr 1;10(7):1031-6. doi: 10.4161/cc.10.7.15067. Epub 2011 Apr 1.
62 Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.Oncotarget. 2018 Feb 16;9(18):14338-14353. doi: 10.18632/oncotarget.24512. eCollection 2018 Mar 6.
63 Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.PLoS Genet. 2009 May;5(5):e1000491. doi: 10.1371/journal.pgen.1000491. Epub 2009 May 22.
64 The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13.Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71. doi: 10.1073/pnas.88.10.4367.
65 Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.Blood. 2013 Sep 19;122(12):2093-103. doi: 10.1182/blood-2012-09-458570. Epub 2013 Aug 7.
66 Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.J Clin Oncol. 1997 May;15(5):1778-85. doi: 10.1200/JCO.1997.15.5.1778.
67 Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia.Blood. 1998 Jul 15;92(2):368-73.
68 Membrane protein hMYADM preferentially expressed in myeloid cells is up-regulated during differentiation of stem cells and myeloid leukemia cells.Life Sci. 2007 Jan 9;80(5):420-9. doi: 10.1016/j.lfs.2006.09.043. Epub 2006 Oct 14.
69 Proto-oncogene TCL1: more than just a coactivator for Akt.FASEB J. 2007 Aug;21(10):2273-84. doi: 10.1096/fj.06-7684com. Epub 2007 Mar 14.
70 The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation.Blood. 2013 Apr 25;121(17):3386-95. doi: 10.1182/blood-2012-11-468868. Epub 2013 Feb 21.
71 Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors.Leuk Lymphoma. 2020 Feb;61(2):409-419. doi: 10.1080/10428194.2019.1672055. Epub 2019 Oct 8.
72 Expression of functional granulocyte colony-stimulating factor receptors on human B-lymphocytic leukemia cells.Ann Hematol. 2000 Mar;79(3):127-31. doi: 10.1007/s002770050567.
73 Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.Leukemia. 2016 Oct;30(10):1968-1978. doi: 10.1038/leu.2016.169. Epub 2016 Jun 13.
74 Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.Blood. 2002 Mar 1;99(5):1505-11. doi: 10.1182/blood.v99.5.1505.
75 TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia.J Hum Genet. 2006;51(4):326-334. doi: 10.1007/s10038-006-0364-y. Epub 2006 Mar 7.
76 Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia.Int J Hematol. 2006 May;83(4):351-5. doi: 10.1532/IJH97.05173.
77 Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency.Mol Cell Biol. 1994 Feb;14(2):1374-82. doi: 10.1128/mcb.14.2.1374-1382.1994.
78 Adult T-cell leukemia: structures and expression of the p53 gene.Int J Cancer. 1991 Dec 2;49(6):880-5. doi: 10.1002/ijc.2910490614.
79 Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.Oncotarget. 2016 Jul 19;7(29):45398-45413. doi: 10.18632/oncotarget.9982.
80 Quantitative Analysis of Interaction Between CADM1 and Its Binding Cell-Surface Proteins Using Surface Plasmon Resonance Imaging.Front Cell Dev Biol. 2018 Aug 7;6:86. doi: 10.3389/fcell.2018.00086. eCollection 2018.
81 Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309.Blood. 2001 Aug 15;98(4):1150-9. doi: 10.1182/blood.v98.4.1150.
82 Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.Cancer Res. 2010 Sep 15;70(18):7336-44. doi: 10.1158/0008-5472.CAN-09-4411. Epub 2010 Sep 7.
83 SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with alpha 5 beta 1 integrin and regulates adhesion of human T cell leukemia virus type 1-infected T cells to fibronectin.J Immunol. 1998 Sep 15;161(6):3087-95.
84 Discordant gene and surface expression of the T-cell receptor/CD3 complex in adult T-cell leukemia cells.Cancer Res. 1991 Nov 15;51(22):6084-8.
85 Effect of tumor promoters on human T cell leukemia/lymphoma virus (HTLV)-structural protein induction in adult T-cell leukemia cells.Cancer Lett. 1984 Sep;24(2):129-39. doi: 10.1016/0304-3835(84)90128-9.
86 Role of TCL1 and ALL1 in human leukemias and development.Cancer Res. 1999 Apr 1;59(7 Suppl):1778s-1783s.
87 The MTCP-1/c6.1B gene encodes for a cytoplasmic 8 kD protein overexpressed in T cell leukemia bearing a t(X;14) translocation.Oncogene. 1994 Dec;9(12):3565-70.
88 MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.Int J Hematol. 2018 Mar;107(3):337-344. doi: 10.1007/s12185-017-2359-1. Epub 2017 Oct 17.
89 Expression of terminal deoxynucleotidyltransferase gene in a case of adult T-cell leukemia.Int J Hematol. 1991 Feb;54(1):37-40.
90 Mutations of the E2F4 gene in hematological malignancies having microsatellite instability.Blood. 2000 Feb 15;95(4):1509-10.
91 Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.Oncogene. 2015 Jul;34(27):3593-604. doi: 10.1038/onc.2014.290. Epub 2014 Sep 22.
92 Elf-2, a rhombotin-2 binding ets transcription factor: discovery and potential role in T cell leukemia.Leukemia. 1997 Jan;11(1):86-96. doi: 10.1038/sj.leu.2400516.
93 Gene expression profile of empirically delineated classes of unexplained chronic fatigue.Pharmacogenomics. 2006 Apr;7(3):375-86. doi: 10.2217/14622416.7.3.375.
94 Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia.Clin Chem. 2014 Jul;60(7):995-1003. doi: 10.1373/clinchem.2013.219956. Epub 2014 May 14.
95 FoxN1-dependent thymic epithelial cells promote T-cell leukemia development.Carcinogenesis. 2018 Dec 31;39(12):1463-1476. doi: 10.1093/carcin/bgy127.
96 His-1 and His-2: identification and chromosomal mapping of two commonly rearranged sites of viral integration in a myeloid leukemia.Oncogene. 1991 Nov;6(11):2041-7.
97 Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line.Mol Cell Biol. 2002 Jun;22(11):3927-41. doi: 10.1128/MCB.22.11.3927-3941.2002.
98 Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia.Cancer Res. 2007 Jun 15;67(12):5699-707. doi: 10.1158/0008-5472.CAN-06-4478.
99 Cell cycle inhibition in human BE-13 T cell leukemia cells by haptoglobin-related (HPR) antisense cDNA.Anticancer Res. 1998 May-Jun;18(3A):1745-50.
100 Expression of human inducible nitric oxide synthase gene in T-cell lines infected with human T-cell leukemia virus type-I and primary adult T-cell leukemia cells.Blood. 1999 Oct 15;94(8):2862-70.
101 An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.J Biol Chem. 2018 May 4;293(18):6844-6858. doi: 10.1074/jbc.RA117.000164. Epub 2018 Mar 14.
102 A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.Genes Dev. 2012 Apr 1;26(7):651-6. doi: 10.1101/gad.186411.111. Epub 2012 Mar 19.
103 Chromosome abnormalities, sister chromatid exchanges, and cell cycle analysis in phytohemagglutinin-stimulated adult T cell leukemia lymphocytes.Cancer Genet Cytogenet. 1985 Feb 1;15(1-2):65-77. doi: 10.1016/0165-4608(85)90131-1.
104 Genetic mapping of two mouse homeobox genes Tlx-1 and Tlx-2 to murine chromosomes 19 and 6.Genomics. 1994 Nov 15;24(2):388-90. doi: 10.1006/geno.1994.1634.
105 The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein.EMBO J. 1990 Feb;9(2):415-24. doi: 10.1002/j.1460-2075.1990.tb08126.x.
106 Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.Haematologica. 2014 Jan;99(1):94-102. doi: 10.3324/haematol.2013.090233. Epub 2013 Aug 23.
107 Simian T cell leukemia virus type I from naturally infected feral monkeys from central and west Africa encodes a 91-amino acid p12 (ORF-I) protein as opposed to a 99-amino acid protein encoded by HTLV type I from humans.AIDS Res Hum Retroviruses. 1997 Mar 20;13(5):425-32. doi: 10.1089/aid.1997.13.425.
108 Superoxide-Generating Nox5 Is Functionally Required for the Human T-Cell Leukemia Virus Type 1-Induced Cell Transformation Phenotype.J Virol. 2015 Sep;89(17):9080-9. doi: 10.1128/JVI.00983-15. Epub 2015 Jun 24.
109 Expression of TGF-beta gene in adult T cell leukemia.Blood. 1988 Jan;71(1):263-6.
110 Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.Leuk Res. 2004 Jan;28(1):71-82. doi: 10.1016/s0145-2126(03)00158-9.
111 Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia.Int J Cancer. 2006 Nov 1;119(9):2090-7. doi: 10.1002/ijc.22026.
112 Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93. doi: 10.1073/pnas.062050599. Epub 2002 Mar 12.
113 The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.Anticancer Drugs. 2009 Jan;20(1):21-31. doi: 10.1097/CAD.0b013e3283144610.
114 A multifunctional domain in human CRM1 (exportin 1) mediates RanBP3 binding and multimerization of human T-cell leukemia virus type 1 Rex protein.Mol Cell Biol. 2003 Dec;23(23):8751-61. doi: 10.1128/MCB.23.23.8751-8761.2003.
115 Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors.Oncogene. 2005 Apr 14;24(16):2695-704. doi: 10.1038/sj.onc.1208334.
116 Possible involvement of RasGRP4 in leukemogenesis.Int J Hematol. 2009 May;89(4):470-481. doi: 10.1007/s12185-009-0299-0. Epub 2009 Apr 7.
117 Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo.Cancer Sci. 2004 May;95(5):411-7. doi: 10.1111/j.1349-7006.2004.tb03224.x.
118 The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.
119 DNA blotting analysis of human retroviruses in cerebrospinal fluid of spastic paraparesis patients: the viruses are identical to human T-cell leukemia virus type-1 (HTLV-1).Int J Cancer. 1988 Aug 15;42(2):221-4. doi: 10.1002/ijc.2910420213.
120 Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.Tumour Biol. 2018 Apr;40(4):1010428318771472. doi: 10.1177/1010428318771472.
121 Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development.Blood. 2018 Sep 20;132(12):1279-1292. doi: 10.1182/blood-2018-02-835850. Epub 2018 Aug 3.
122 Testican 3 expression in adult T-cell leukemia.Leuk Res. 2009 Jul;33(7):913-8. doi: 10.1016/j.leukres.2008.11.006. Epub 2009 Jan 13.
123 Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia.Blood. 2013 May 23;121(21):4340-7. doi: 10.1182/blood-2012-08-446922. Epub 2013 Mar 28.
124 The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses.Ann Intern Med. 1986 Oct;105(4):560-72. doi: 10.7326/0003-4819-105-4-560.
125 Rat lymphoid cell lines with human T cell leukemia virus production. I. Biological and serological characterization.J Exp Med. 1984 Apr 1;159(4):1105-16. doi: 10.1084/jem.159.4.1105.
126 Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis.Cancer Res. 2004 Feb 15;64(4):1287-92. doi: 10.1158/0008-5472.can-03-0908.
127 T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis.Bone. 2009 Oct;45(4):627-39. doi: 10.1016/j.bone.2009.06.019. Epub 2009 Jun 25.
128 A B-cell line having chromosome 14 aberration at break band q11 derived from an adult T-cell leukemia patient.Jpn J Cancer Res. 1988 Jan;79(1):12-6. doi: 10.1111/j.1349-7006.1988.tb00004.x.
129 Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death.Apoptosis. 2013 Aug;18(8):963-79. doi: 10.1007/s10495-013-0842-6.
130 HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes.AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1047-61. doi: 10.1089/088922201300343735.
131 ETV6 mutations in early immature human T cell leukemias.J Exp Med. 2011 Dec 19;208(13):2571-9. doi: 10.1084/jem.20112239. Epub 2011 Dec 12.
132 Novel Interactions between the Human T-Cell Leukemia Virus Type 1 Antisense Protein HBZ and the SWI/SNF Chromatin Remodeling Family: Implications for Viral Life Cycle.J Virol. 2019 Jul 30;93(16):e00412-19. doi: 10.1128/JVI.00412-19. Print 2019 Aug 15.
133 SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3K) inhibitors.Eur J Med Chem. 2017 Jan 5;125:1156-1171. doi: 10.1016/j.ejmech.2016.11.014. Epub 2016 Nov 9.